KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Conditions
Non Small Cell Lung Cancer
Trial Phase
Trial Purpose and Description
Trial Purpose
This is a research study designed to look at the effects of an investigational chemotherapy drug, KD019, on non small cell lung cancer in comparison to a standard chemotherapy drug, Erlotinib ( Tarceva®).
Participation Guidelines
- Age:
- 18 Years and older
- Gender:
- Both
Eligibility Criteria
Criteria For Eligibility subjects must have: • failed one or two previous courses of therapy. • have no active brain metastasis. Treated non-active brain metastasis are acceptable. • cannot have received an EGFR inhibitor (Tarceva[erlotinib] or Iressa[gefitinib]) in the past. • has demonstrated progressive disease.
|
- Sponsor:
- Kadmon Corporation, LLC
- Dates:
- November 2012
- Last Updated:
- Study HIC#:
- 1204010034
Clinicaltrials.gov ID: Yale4409252
